MedTrace Logo

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

NCT07428486 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-05-07

No results posted yet for this study

Summary

To find safe and effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy in patients with relapsed/refractory T-ALL.

Conditions

  • Phase I
  • FLAG Chemotherapy
  • Lisaftoclax
  • Pelcitoclax
  • Relapsed/Refractory
  • Lymphoblastic Leukemia Acute

Interventions

DRUG

Fludarabine

Given by IV

DRUG

Cytarabine

Given by IV

DRUG

G-CSF

Given by Injection

DRUG

Lisaftoclax

Given by Po

DRUG

Pelcitoclax

Given by Iv

Sponsors & Collaborators

  • Ascentage Pharma Group Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Nicholas J Short, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2026-04-27
Completion
2026-04-27
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07428486 on ClinicalTrials.gov